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ABSTRACT
Introduction Hepatitis C virus (HCV) is a global public 
health threat, and novel models of care are required 
to treat those currently or previously at highest risk of 
infection, particularly persons who inject drugs (PWID; 
ever injected), as conventional healthcare models do not 
have the reach to deliver cure of HCV to disadvantaged, 
disproportionately affected communities. In Western 
Europe and Australasia, it is estimated that HCV affects 
between 0.4% and 1.0% of the regions’ populations, 
accordingly, it affects between 0.4% and 0.7% of the 
populations of countries in this study (Scotland, Wales 
and Australia). Reaching mEthadone users Attending 
Community pHarmacies with HCV (REACH HCV) will 
evaluate community pharmacy- based diagnostic outreach 
and HCV treatment against conventional HCV testing and 
treatment pathways for clients receiving opioid substitution 
therapy (OST) in community pharmacies.
Methods and analysis REACH HCV is an international 
multicentre cluster randomised controlled trial with sites 
in Scotland, Wales and Australia. The sites are community 
pharmacies which are randomised equally to one of two 
pathways: the pharmacy intervention pathway or the 
education- only (control) pathway. Participants are recruited 
from OST clients in these pharmacies.
In the pharmacy intervention pathway, participants receive 
a rapid point- of- care HCV PCR test in their pharmacy by 
a study outreach nurse. If positive, direct- acting antivirals 
(DAAs) are delivered to participants via their pharmacist in 
line with their OST schedule.
In the education- only pathway, pharmacists counsel OST 
clients on HCV and refer them to the nearest nurse- led 
clinic or general practitioner offering HCV testing according 
to standard care protocols. If positive, DAAs are delivered 
as in the intervention pathway.
The primary endpoint for both pathways is sustained 
viral response at 12 weeks post- treatment . Secondary 
outcomes are: cost- efficacy by pathway; participants 
tested by pathway; adherence to therapy by pathway and 
impact of blood test results on treatment decisions.
A statistical analysis plan will be finalised prior to data 
lock. Analysis will be by intention to treat (ITT) to show 
superiority. Modified ITT analysis will also be undertaken to 
explore the steps in the pathways.
Ethics and dissemination The trial received ethical 
favourable opinion from the East of Scotland Research 
Ethics Committee 2 (19/ES/0025) for UK sites and approval 
from the Alfred Hospital Ethics Committee (148/19) for 
Australian sites and complies with principles of Good 
Clinical Practice. Final results will be presented in peer- 
reviewed journals and at relevant conferences.
Trial registration number  ClinicalTrials. gov Registry 
NCT03935906.
Protocol version V.4.0—19 March 2020.
INTRODUCTION
Background
Viral hepatitis is a serious public health threat 
which contributes substantially to the global 
burden of liver- related health complications. 
Of the 1.4 million deaths attributable to viral 
hepatitis annually, 48% are due to hepatitis C 
virus (HCV), which is spread through blood- 
to- blood contact.1 There are an estimated 
71.1 million viraemic HCV infections glob-
ally, representing a worldwide disease burden 
of about 1% of the population.2 In Western 
Europe and Australasia, it is estimated that 
HCV viraemia affects between 0.4% and 1.0% 
of the regions’ populations.2 In line with that, 
chronic HCV affects between 0.4% and 0.7% 
of the populations of countries (Scotland, 
Strengths and limitations of this study
 ► Pragmatic test- and- treat trial based in community 
pharmacies which decentralises hepatitis C virus 
(HCV) care.
 ► Complements health policy encouraging primary 
care providers to engage in HCV through care.
 ► All aspects of the HCV cascade of care located on 
site in the intervention arm.
 ► The trial population is stable opioid substitution ther-
apy clients, limiting the results’ applicability at- risk 
groups who lead a less predictable lifestyle.
 on A









pen: first published as 10.1136/bm





2 Byrne C, et al. BMJ Open 2020;10:e036501. doi:10.1136/bmjopen-2019-036501
Open access 
Wales and Australia) in this study.3–6 A common HCV 
transmission route in high- income countries like these is 
injection drug use.
While recovering from substance use, including 
injecting drug use, many individuals will be prescribed 
a course of managed opioid substitution therapy (OST), 
typically by a general practitioner (GP), which is dispensed 
by a community pharmacist. Around 40% of individuals 
receiving OST could be infected with HCV,7 therefore 
test and treat initiatives in this population are required to 
progress towards WHO HCV elimination targets.1 Recent 
data estimates HCV antibody prevalence of between 49% 
and 57% among persons who inject drugs (PWID) in 
Scotland, Wales and Australia.8–10
Recommended standard care in jurisdictions in this 
trial is to offer those with a history of injecting drug use 
regular HCV testing,11 12 often through drug treatment 
services or GPs, but there is significant variation in the 
availability and the offer of testing. Typically individuals 
reactive for HCV are referred to a secondary care- led 
viral hepatitis service. Under this model, approximately 
50%–66% of PWID attending needle exchanges in our 
jurisdictions self- report as aware of their HCV status or 
having been tested in the last 12 months,9 10 although 
few had initiated treatment. These figures indicate HCV 
testing among PWID could be improved and suggests new 
models should be explored which integrate HCV care 
into new environments.
Studies have supported the provision of testing and treat-
ment for HCV via community pharmacies.7 13 14 However, 
research assessing HCV care in community settings 
suggest that only between 15% and 18% of individuals 
testing positive for HCV then commence treatment,8 15 
with further population- level observations noting an only 
12% treatment uptake.16 This suggests a significant 
disparity between confirmation of infection in commu-
nity settings and commencing treatment.
Despite the evidence noted7 13 14 for up- skilling commu-
nity pharmacy staff to test and treat for HCV, in some 
instances it may not be resource- efficient to do so; for 
example, in pharmacies with few OST clients, staff will 
struggle to maintain competence in testing. Further, in 
the time it takes train staff to competence, an outreach 
nurse could feasibly have tested the client cohort.
Rationale
This trial will address the need to increase HCV testing 
rates among PWID, and linkage to treatment for those 
testing HCV positive, by the provision of a novel pathway 
of care for persons in receipt of OST in community phar-
macies using an outreach nurse to test and assess indi-
viduals, and then provide direct- acting antiviral (DAA) 
treatment. The aims of this trial support the implementa-
tion of national HCV policy in the UK and Australia17–20 
by embedding all elements of the HCV care cascade in a 
community setting, thereby testing whether that model 
increases HCV testing coverage and improves linkage to 
care.
PWID are subject to significant societal and systems- 
wide stigma linked to their drug use,21 which disincentiv-
ises them from presenting to health services for screening 
and treatment of HCV,22 and embedding full HCV care 
in community settings offers an opportunity to negate 
that. Recent work explored the most valued attributes of 
a service delivering HCV care. OST clients’ most valued 
preferences were to be treated in a familiar environment 
and to be treated with respect.23 In a community phar-
macy, individuals have a regular and familiar point of 
contact with the healthcare service that they highly value; 
they also have an incentive to attend and interact in this 
setting due to OST. Co- locating test and treat services 
within community pharmacies has been identified as 
a valuable addition to HCV care by PWID in receipt of 
OST.24 The strength of the patient- pharmacist relation-
ship offers a clear rationale for co- locating HCV testing 
and treatment in community pharmacies for those 
receiving OST.24 25
The safety and efficacy profile of DAAs26 can allow 
the rationalisation of supply and management of treat-
ment in less complex cases of infection. Combining DAA 
treatment with point- of- care (PoC) testing which enables 
straight- to- PCR analysis in a short time could produce 
a streamlined pathway of care which reduces waiting 
time for diagnostic results, and decreases the number 
of required on- treatment visits for patients. This trial is 
designed to have minimal on- treatment monitoring for 
participants, while also leveraging the support of their 
community pharmacy to promote adherence.
Objectives
The primary objective is to compare the efficacy of the 
pharmacist- intervention pathway with the education- only 
pathway for proportion of participants achieving a cure 
following DAA treatment for HCV. The outcome measure 
is sustained viral response at 12 weeks post- treatment 
(SVR12), which is measured 12 weeks post- HCV treatment 
completion.
Secondary outcomes are cost- effectiveness by pathway; 
participants tested by pathway; adherence to therapy by 




Sponsorship for sites in the UK is provided via a joint 
agreement between Tayside Health Board and the 
University of Dundee; for Australian sites, this is provided 
by the Alfred Hospital. Overall administration of the trial 
is provided by Tayside Clinical Trials Unit (TCTU), a UK 
Clinical Research Collaboration (UKCRC)- registered 
clinical trials unit.27 Trials conducted by TCTU are 
subject to independent ad- hoc audit by the study sponsor 
and its representatives, as well as relevant regulatory 
authorities (eg, the Medicines and Healthcare products 
Regulatory Agency (MHRA)). Protocol modifications 
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are communicated to relevant authorities by the TCTU 
trial coordinator or delegated individual. There is a 
Trial Management Group (TMG) in place for the trial 
comprised of the study investigators, TCTU management 
and coordinating staff, and National Health Service care 
network staff. The role of the TMG includes, but is not 
limited to:
 ► To provide advice on all appropriate aspects of the 
trial.
 ► To provide advice to the study investigators.
 ► To adjudicate on future continuation (or otherwise) 
of the trial.
 ► To monitor recruitment and strategise if required.
 ► To review and consider issues relating to data manage-
ment and integrity.
 ► To review and consider proposals for interim analyses.
 ► To review and consider site deviations/breaches of 
protocol.
 ► To oversee timely publication of results.
 ► To review approve external requests for data or subsets 
of data.
Trial design
This trial is an international, multicentre, cluster- 
randomised two- arm unblinded trial of pharmacy 
outreach PoC HCV diagnosis and DAA treatment versus 
conventional test- and- treat pathways for clients receiving 
OST in community pharmacies in Scotland, Wales 
and Australia. There are two pathways the pharmacy- 
intervention pathway and education- only (control arm) 
pathway.
Patient and public involvement
Patient or public involvement groups were not involved 
in the design of this study. Study design was developed 
from prior experience of the investigators of working 




 ► Over 18 years of age.
 ► Previous or current injecting drug user.
 ► Stable OST dose for greater than 12 weeks prior to 
study enrolment.
 ► Glecaprevir/pibrentasvir treatment naïve.
 ► Able to voluntarily sign and date an informed consent 
form prior to initiation of any screening or study- 
specific procedures.
 ► Able to understand and adhere to study visit schedule 
and all other protocol requirements mandatory field
Exclusion criteria
 ► Female who is pregnant, planning to become preg-
nant, or breastfeeding, or unwilling/unable to take 
appropriate birth control.
 ► Known current HIV infection.
 ► Known current hepatitis B virus (HBV) infection. 
Serological: patients with a positive hepatitis B surface 
antigen (HBsAg) or isolated positive hepatitis B core 
antigen (anti- HBC) will be excluded from the study 
and followed up in secondary care.
 ► Previous treatment with glecaprevir/pibrentasvir.
 ► Currently taking any concomitant medication that has 
a warning of ‘do not co- administer’ with glecaprevir 
and/or pibrentasvir as defined by the Liverpool Hep 
drug interactions website ( www. hep- druginteractions. 
org) and product SmPC.
 ► Clinically significant abnormalities that make candi-
date unsuitable for this study in the opinion of the 
investigator including but not limited to:
Uncontrolled cardiac, respiratory, gastrointestinal, 
haematologic, neurologic, psychiatric or other med-
ical disease or disorder, which is unrelated to existing 
HCV infection.
 ► History of either current or previous decompensated 
liver disease or symptoms/signs of decompensation, 
for example, ascites noted on physical examination, 
use of beta- blockers for portal hypertension, hepatic 
encephalopathy or oesophageal variceal bleeding.
 ► Candidate is deemed unsuitable to receive study drugs 
by the study investigator, for any reason according to 
clinical judgement.
 ► Unable or unwilling to provide informed consent.
 ► History of severe, life- threatening or other significant 
sensitivity to any excipients of the study drugs.
 ► Drug- drug Interaction which may have safety concerns 
with any concomitant medication the patient is 
receiving, including non- prescribed and/or recrea-
tional drugs.
Study setting
HCV testing, administration of DAA treatment, and data 
collection visits occur in community pharmacies in the 
pharmacy- intervention pathway. In the education- only 
pathway, these occur in alignment with standard care. All 
participant enrolment occurs in community pharmacies.
Enrolment
Participants will be recruited from OST client cohorts in 
community pharmacies in Scotland, Wales and Australia. 
Up to 140 HCV- positive participants will be treated, 
requiring up to 345 to be enrolled. Informed consent will 
be obtained by a study or clinic nurse and community 
pharmacists. Participant information documents will be 
made available in Welsh for any individuals who request 




The PoC device being used for the trial is supplied by 
Genedrive Diagnostics . It is a compact CE- IVD (In Vitro 
Diagnostics) marked device, which incorporates ultra- fast 
PCR cycling. The device is suitable for use by operators 
after minimal training and provides a simple positive/
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negative reading in under 90 min from the sample collec-
tion. The device requires 30 µL of sample.28 This test is 
administered at baseline for participants in the pharma-
cist intervention arm.
HCV medication
The study will use glecaprevir/pibrentasvir 100 mg/40 
mg film- coated tablets provided by AbbVie, the funder. 
Dosage is three tablets taken once daily.
Participants will be prescribed this based on the 
following criteria:
All genotypes will receive 8 weeks of treatment, if they 
are HCV treatment- naïve and have an AST to Platelet 
Ratio Index (APRI) score of ≤1.
Patients with APRI >1 will be evaluated with a further 
test (eg, Fibroscan). This will take place following 
commencement of therapy. There will be no change to 
therapy if results are consistent with portal fibrosis (F) 
F0–F3; if results are consistent with F4, participants will 
have their treatment regimen extended by 4 weeks, to a 
total of 12 weeks.
Enrolled patients who have previously failed therapy 
with PEGylated- Interferon + ribavirin ± sofosbuvir or 
sofosbuvir + ribavirin will be prescribed:
 ► Genotypes 1, 2, 4, 5 and 6 will receive 8 weeks if their 
APRI is ≤1. Patients with APRI >1 will be evaluated 
with a further test as previously outlined. Treatment 
changes will be as previously outlined.
 ► Genotype 3: 16 weeks (regardless of APRI score).
In Australia, in the education- only arm, any DAA can be 
prescribed in line with national prescribing guidelines.29
Study pathways
Pharmacy-intervention pathway
In this pathway, staff training and educational materials 
on HCV will be delivered by the trial team to pharma-
cists. In the immediate period prior to opening to patient 
consent, the pharmacist will discuss HCV with OST clients 
to raise awareness of HCV and provide study literature.
The outreach nurse will attend the pharmacy to take 
informed consent from interested OST clients. From 
those agreeing to be tested, the nurse will perform 
conventional venepuncture, taking blood for PoC testing 
and additional tubes for full blood count, urea and 
electrolytes, liver function testing, including markers 
of liver fibrosis (Fibrosis-4 Index, APRI, aspartate trans-
aminas to alanine transaminase ratio (AST:ALT ratio)), 
and viral parameters (HCV, HIV and HBV). A baseline 
blood sample per participant will be stored in a −80°C 
freezer for viral resistance assessment in the event of non- 
response to DAA treatment despite adherence.
At a subsequent visit, HCV- positive participants will be 
assessed for DAA treatment by the nurse and complete 
questionnaires collecting demographic and injecting 
behaviour information, and the EQ- 5D- 5L.30–36 DAA 
treatment will be arranged—with support from tertiary 
multidisciplinary teams if required—by the nurse using a 
patient group direction in the UK, and by the principal 
investigator in Australia.37 Treatment will be dispensed by 
the community pharmacist in line with the participant’s 
OST schedule. Adherence to treatment will be recorded 
by the community pharmacist.
Participants who test negative following the PoC test will 
be informed their result is expected to be accurate, but must 
be confirmed by the central laboratory using the sample 
taken for viral parameters. Those who are confirmed HCV 
PCR negative will be revisited or telephoned by the nurse to 
confirm their status; any eligible patients who are PCR posi-
tive, but were below the limit of detection of the PoC device,28 
will then be commenced on treatment.
The next study visit will be at least 12 weeks post- treatment 
when the nurse will conduct a PoC HCV test, and partici-
pants will complete further study questionnaires.
Education-only pathway
In this pathway, staff training and educational materials 
on HCV will be delivered as in the pharmacy intervention 
pathway. The community pharmacist will, as in recom-
mended standard practice,20 38 39 opportunistically discuss 
HCV with OST patients. Information will be relayed verbally 
and via standard health service HCV literature. Study infor-
mation will also be distributed. Patients will be advised to 
attend the nearest nurse- led clinic (in UK) or referred to 
their GP (in Australia) for HCV testing and assessment via 
standard care protocols. OST clients will be provided with a 
study reply slip to identify their pharmacy when presenting 
for enrolment. Should they attend without this, their phar-
macy can be confirmed directly with their pharmacist.
Eligible patients will be consented to the trial by the clinic 
nurse (UK), or pharmacist (Australia). Questionnaires and 
follow- up, as previously described, will be completed in align-
ment with standard care.
For eligible participants: DAA treatment will be arranged, 
treatment will be dispensed and follow- up conducted, in line 
with standard care in all settings. Adherence will be recorded 
as outlined previously. The SVR12 blood test will occur in the 
local clinic or GP offering this.
Participant journey
In the pharmacist- intervention pathway, all participants 
receive three or four data collection visits with the outreach 
nurse in their community pharmacy, depending on the result 
of their baseline PoC test. In the education- only pathway, all 
participants receive three data collection visits aligned with 
standard care schedules.
Participant visit schedules are fully outlined in tabular 
form in online supplementary file ‘Study schedule matrices 
delineated by pathway’, an overview is presented in figure 1.
OUTCOMES AND ANALYSIS
Primary outcome
As outlined in table 1, the primary outcome (SVR12) will 
be assessed as a binary outcome for subjects and so will 
use logistic regression modelling while accounting for 
clustering through generalised linear mixed models. This 
will be analysed on an intention- to- treat (ITT) basis. The 
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numerator will be the number of participants who achieve 
SVR12, and the denominator will be the total number of 
patients on OST. Additionally, results will be expressed as 
a proportion of known HCV- infected subjects.
Secondary outcomes
As outlined in table 2, secondary outcomes will be 
assessed in the same manner, initially as ITT with all 
eligible patients as the denominator and by modified ITT 
(mITT) to explore the steps in the pathways. The mITT 
population will contain all enrolled subjects who tested 
positive for HCV.
The mITT analyses will include:
 ► Percentage of patients achieving SVR12 in each arm.
 ► Proportion who start HCV treatment within the dura-
tion of the study in each arm.
 ► Proportion of those initiating treatment that complete 
the treatment course (≥85% adherence).
Descriptive analyses will be performed to evaluate 
patient- level and pharmacy- level baseline characteristics 
for the overall population and appropriate subgroups.
Sample size calculation
As the pharmacist intervention pathway is a specific 
population- based intervention for diagnosis and treat-
ment, the number of clients on OST treatment at each 
pharmacy is the known factor. HCV status of individuals 
within the pharmacy will be unknown at study commence-
ment, so the number of clients on OST in pharmacy will 
be the target for trial setup.
Variability has been demonstrated in the proportion of 
individuals on OST who are HCV positive, with figures 
Figure 1 Participant journey overview. The participant journey through the study is displayed per pathway. In the pharmacy- 
intervention pathway, participants are screened for hepatitis C in their community pharmacy by the study nurse using the 
Genedrive point- of- care test. If positive and eligible for the study, they are assessed for treatment with direct- acting antivirals 
by the nurse and commence treatment in their pharmacy. They are then followed- up in their pharmacy at least 12 weeks after 
finishing treatment to check for a sustained viral response. In the education- only pathway, participants are referred to their local 
clinic or GP for hepatitis C screening. If positive, they are prescribed in line with standard care. Treatment is dispensed by their 
pharmacist and they are referred to their local clinic or GP for a sustained viral response test. AUS, Australia, DAA, direct acting 
antiviral; GP, general practitioner; HCV, hepatitis C virus; OST, opiate substitution therapy; PoC, point of care; SVR12, sustained 
viral response at 12 weeks.
Table 1 Primary objective and outcome measure
Primary objective Outcome measure Time point of outcome measured
To evaluate the difference in rates of 
diagnosis and cure of HCV in patients 
receiving OST between the pharmacy- 
intervention and education- only pathways.
Proportion of patients in a population of 
stable OST clients achieving SVR12 in the 
pharmacy- intervention pathway versus 
education- only pathway (Intention to Treat).
At least 12 weeks after participants 
finish their HCV treatment.
HCV, hepatitis C virus; OST, opiate substitution therapy; SVR12, sustained viral response at 12 weeks.
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reported at approximately 40%.40 41 The power calcula-
tion for the study is based on the assumption that each 
pharmacy will have approximately 4 HCV positive OST 
clients (assuming around 10 OST clients per pharmacy) 
who could be identified and assessed for treatment.
The study is powered on SVR12, that is, the difference in 
proportions of those HCV positive on OST who achieve 
SVR12. Currently, this is estimated to be 2.5%, and it is 
anticipated the study will achieve 25%. For a parallel- 
group design, the number required per arm would be 
n=48, so 96 in total with 90% power and a two- sided alpha 
of 0.05. Allowing for clustering, by assuming four patients 
per pharmacy and an intracluster correlation of 0.05, 
then the inflation factor is 1.15 and gives a total of 112. If 
we assume 20% drop out, then the total number required 
is 140, and with four patients per pharmacy on average 
this would require 35 pharmacies. Given the cluster 
randomised design, the aim is to recruit up to 50 phar-
macies, which will help reduce intracluster correlation. 
Estimation was based on software nQuery Advisor V.7 and 
confirmed by an independent statistician using GPower.
Randomisation
The unit of randomisation is the pharmacy. Up to 50 phar-
macies will be randomised to either the pharmacist inter-
vention or the education- only pathway on a 1:1 per- hub 
basis (Scotland, Wales and Australia). Randomisation will 
be conducted at the UK Clinical Research Collaboration 
registered TCTU, University of Dundee, UK.
Statistical methods
To account for the clustered nature of the trial, a mixed- 
effects logistic regression model will be performed with 
the parameter indicator of a trial arm in the model, 
and a random parameter to account for within- cluster 
correlation.
As all patients will have either achieved SVR12 or not, 
and we will assume that drop- outs/lost to follow- up are 
failures, there will be no missing data in the primary 
outcome. Extra- binomial variability or over- dispersion, 
as well as the number of zeros, will be examined in the 
logistic model and, if present, alternative modelling 
such as negative binomial models and zero- inflated 
negative binomial models will be considered. This will 
also be adjusted by prior therapy and genotype; the two 
factors are interdependent, determining the length of 
therapy.
Multiple logistic regression modelling will explore the 
patient and pharmacy characteristics associated with the 
primary/secondary outcomes. Analyses will be carried 
out in accordance with the pre- specified statistical anal-
ysis plan (SAP).
Health economic analysis
In this analysis, an existing dynamic, deterministic model 
of HCV transmission, progression and HCV treatment 
among PWID to evaluate the impact of the pharmacy 
intervention pathway compared with standard care testing 
and treatment will be adapted.42 A Bayesian parameter 
sampling and model calibration process will be used to 
take account of uncertainty in key factors (eg, injecting 
duration, HCV disease progression rates, health utili-
ties, death rates and HCV prevalence) to generate HCV 
epidemic profiles consistent with each study hub. The 
model will then be run with and without the intervention 
to project the degree to which the intervention results in 
additional benefits.
Table 2 Secondary objectives and outcome measures
Secondary objective Outcome measure
Time point of outcome 
measured
Determine which pathway leads 
to more people on OST who are 
confirmed HCV RNA positive being 
treated and cured.
Percentage of patients achieving SVR12 from the 
patient population that tested positive for HCV in each 
arm (modified intention to treat).
At least 12 weeks after 
participants finish their HCV 
treatment.
Evaluate if the pharmacist- intervention 
pathway is more cost- effective than 
the education- only pathway, from 
the perspective of the NHS (UK) and 
Medicare (Australia).
Incremental cost- effectiveness ratio to consider the 
epidemiological impact of scaling up the intervention 
to all pharmacies in a specific setting in Australia, 
Scotland and Wales; and cost- benefit calculations. 
Lifetime horizon between 10–20 years.
End of Study.
Determine which pathway leads to 
more people on OST being tested for 
HCV.
Proportion of patients being tested for HCV in each 
arm.
End of study.
Compare adherence and persistence to 
HCV therapy in each pathway.
Proportion of patients adhering to therapy in each arm 
(taking ≥85% of prescribed tablets) as reported in the 
observed therapy adherence log.
End of study.
Assess the impact of baseline blood 
tests on treatment decisions.
Proportion of patients in whom changes in therapy 
are advised due to blood test results, as recorded at 
start of HCV therapy.
Prior to treatment.
HCV, hepatitis C virus; NHS, national health service; OST, opiate substitution therapy; SVR12, sustained viral response at 12 weeks.
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The economic analysis will be performed from a 
UK National Health Service and Australian Medicare 
perspectives with health utilities (in quality- adjusted life 
years; QALY) attached to each model compartment, and 
costs attached where relevant.
The effect of the intervention on HCV infections averted 
and QALY saved will be projected by the model. Results 
will be presented as mean incremental cost- effectiveness 
ratio. The probability that the intervention is cost- effective 
will be estimated for different willingness- to- pay (WTP) 
thresholds (£20 000 or £30 000 per QALY as used by the 
National Institute for Health and Care Excellence), and 
£13 000 in line with a recent estimate43 of where the UK 
WTP should lie. Cost- effectiveness acceptability curves 
will be constructed and univariate sensitivity analyses 
undertaken, with analysis of covariance methods being 
used to summarise the proportion of the variability in 
the incremental costs and QALY explained by the uncer-
tainty in input parameters. Univariate sensitivity analyses 
will consider such things as changes in the: time horizon; 
discount rates; PWID HCV chronic prevalence; changes 
to the treatment costs and coverage of the intervention. 
We will also explore the effect of assuming no prevention 
benefit (but allowing for re- infection), by permanently 
fixing the force of infection, independent of numbers of 
infected individuals.
The model will also be used to consider the epidemio-
logical impact of scaling up the intervention to all phar-
macies in Dundee, Cardiff and Melbourne over a 10 and 
20- year timeframe.
Data collection and management
Individual participant data collected at each visit will be 
recorded in a paper case report form (CRF). Anonymised 
data will be stored, with participants only distinguishable 
by study identification number. No personal informa-
tion is shared outside the participants’ local clinical care 
networks. Data on participant adherence to therapy are 
collected in a dispensing and adherence log. Screening 
data will be collected from screening logs completed by 
pharmacists. Data will be transferred to an electronic 
data management system provided by the University of 
Dundee. Once data entry is complete, management and 
quality control will be conducted in line with Tayside 
Medical Science Centre SOP DM053: Data management 
in clinical research.
Data integrity will be monitored on an ongoing basis 
by the TMG.
Safety reporting
All adverse events (AEs) or serious adverse events (SAEs) 
will be recorded on the AE log in each participant’s CRF 
and will be assessed by the chief investigator or appropri-
ately qualified delegate. AEs and SAEs will be recorded 
from the time a participant joins the study until their last 
study visit. Participants with outstanding AEs or SAEs at 
the end of the study will be referred by the study team to 
appropriate onward medical care.
Owing to the significant level of comorbid disease and 
illness that are expected to present in this population, the 
investigators will record as AEs/SAEs, but not report as 
SAEs, in the following categories:
 ► Hospitalisation for assault or accidental injury.
 ► Hospitalisation for preplanned surgery.
 ► Worsening of pre- existing comorbidity.
 ► Hospitalisation for abscesses due to drugs use.
 ► Infectious complications of drug use.
 ► Hospitalisation for wound management due to drugs 
use.
 ► Any death or hospitalisation due to new cardiovas-
cular events.
 ► Any death or hospitalisation due to new diagnosis or 
treatment of cancer.
 ► Any death or hospitalisation due to infection.
 ► Any admission for elective or planned investigation or 
treatment.
 ► Any death or hospitalisation for deteriorating renal 
function, high or low potassium levels.
 ► Any hospitalisation due to nausea, vomiting, constipa-
tion or diarrhoea.
Ethics and dissemination
The research will be conducted in line with the principles 
of the Declaration of Helsinki and in accordance with 
the Research Governance Framework Scotland, the UK 
Policy Framework for Health and Social Care Research, 
and the Australian Code for the Responsible Conduct of 
Research. Ethical favourable opinion was gained from 
East of Scotland Research Ethics committee for UK sites 
(19/ES/0025) and the Alfred Hospital Ethics Committee 
(149/19).
Results will be disseminated through peer- reviewed 
publications, presented at conferences and published 
on  clinicaltrials. gov. Anonymised Individual Participant 
Data (IPD) will be retained by the study team. Ownership 
of the data arising from this study resides with the study 
team and their respective employers. The study team will 
follow the International Committee of Journal Editors 
(ICJME) guidelines. Access to IPD will be considered 
for researchers who supply a methodologically sound 
proposal. Access will be granted in line with prevailing 
recommendations44 via a reputable online controlled 
access repository. Requests for data access should be sent 
to the corresponding author (ORCID: 0000-0002-7586-
7712). Data which may be shared include all IPD collected 
during the trial which underlies the final published 
results, after de- identification; the study protocol; the 
SAP; the data anagement plan.
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